Project: Anti B-Cell 2-specific Antibody for the treatment of chronic Lymphocytic Leukaemia

ABC2ALL consortium will develop a novel therapeutic strategy to treat B-cell chronic lymphocytic leukemia (CLL). The consortium will design, produce and validate a therapeutic bispecific monoclonal antibody (mAb) that simultaneously targets two specific receptors expressed on malignant B-cells. This will provide improved efficacy, specificity, and safety when compared to the current treatment regimens. Upon completion of the project, the product will be ready for further clinical development.

Acronym ABC2ALL (Reference Number: 10506)
Duration 15/11/2016 - 15/11/2019
Project Topic Biological Sciences / Technologies
Network Eurostars 2
Call Eurostars Cut-Off 5

Project partner

Number Name Role Country
24304 MabSolys SAS Coordinator France
24305 Absolute Antibody Ltd. Partner United Kingdom
24306 Biotechpharma UAB Partner Lithuania
24307 Academisch Medisch Centrum, Universiteit van Amsterdam Partner Netherlands